Osiris Therapeutics (OSIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2018 | 09-2018 | 06-2018 | 03-2018 | 12-2017 | |
| Sales | 40,823 | 36,491 | 33,876 | 31,634 | 32,576 |
| Cost of Goods | 9,806 | 9,808 | 9,672 | 8,853 | 9,276 |
| Gross Profit | 31,017 | 26,683 | 24,204 | 22,781 | 23,300 |
| Operating Expenses | 25,595 | 23,531 | 22,711 | 26,134 | 23,870 |
| Operating Income | 6,228 | 3,960 | 2,165 | -2,500 | -294 |
| Other Income | 127 | -21 | 353 | 216 | 726 |
| Pre-tax Income | 6,355 | 3,939 | 2,518 | -2,284 | 432 |
| Income Tax | -26,175 | 100 | 34 | 36 | -1,264 |
| Net Income Continuous | 32,530 | 3,839 | 2,484 | -2,320 | 1,696 |
| Net Income Discontinuous | N/A | 368 | N/A | N/A | 210 |
| Net Income | $32,530 | $4,207 | $2,484 | $-2,320 | $1,906 |
| EPS Basic Total Ops | 0.95 | 0.12 | 0.07 | -0.07 | 0.06 |
| EPS Basic Continuous Ops | 0.95 | 0.11 | 0.07 | -0.07 | 0.05 |
| EPS Basic Discontinuous Ops | N/A | 0.01 | N/A | N/A | 0.01 |
| EPS Diluted Total Ops | 0.95 | 0.12 | 0.07 | -0.07 | 0.06 |
| EPS Diluted Continuous Ops | 0.95 | 0.11 | 0.07 | -0.07 | 0.05 |
| EPS Diluted Discontinuous Ops | N/A | 0.01 | N/A | N/A | 0.01 |
| EPS Diluted Before Non-Recurring Items | N/A | 0.11 | 0.07 | N/A | N/A |
| EBITDA(a) | $6,443 | $4,192 | $2,380 | $-2,289 | $-124 |